Relapsed Cancer Clinical Trial
Official title:
Study of Metabolic, Genomic and Proteomic Modifications in Relapsed Glioblastoma. Identification or Prognostic Markers in Patients Undergoing Surgery for Relapsed Glioblastoma.
Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and potential new therapeutic targets.
Glioblastomas are the most frequent and aggressive malignant Central Nervous System (CNS) tumors in adults, with a median survival of only 14 months. Current treatment is based on surgery followed by radiochemotherapy (STUPP protocol), unchanged since 2005. Clinical trials evaluating immune checkpoint inhibitors and targeted therapies have largely failed to demonstrate efficacy in these tumors. In order to better understand the oncogenesis of glioblastoma and identify potential new therapeutic targets, the study of the characteristics of relapsed tumors compared with the initial tumor seems relevant. The aim of this retrospective study is to investigate the transcriptomic, proteomic and metabolic characteristics of relapsed glioblastomas reoperated at the University Hospital of Bordeaux, France, between 2005 and 2023, for which tumor material is available. These analyses will be correlated with relapse-free and overall survival of the patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03336931 -
PRecISion Medicine for Children With Cancer
|
||
| Recruiting |
NCT05852717 -
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
|
Phase 2 | |
| Terminated |
NCT04092179 -
Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06024603 -
Individualized Treatments in Adults With Relapsed/Refractory Cancers
|
N/A | |
| Active, not recruiting |
NCT03187288 -
Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS
|
Phase 1 | |
| Recruiting |
NCT04292119 -
Lorlatinib Combinations in Lung Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04310345 -
Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents
|
N/A | |
| Recruiting |
NCT05274451 -
A Study to Investigate LYL797 in Adults With Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05662397 -
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05922501 -
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT04275102 -
Three Times Weekly Symptom Screening for Children With Cancer
|
N/A | |
| Recruiting |
NCT06004167 -
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
|
N/A | |
| Recruiting |
NCT05631574 -
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
|
Phase 1 | |
| Completed |
NCT03765099 -
Animal-Assisted Interactions in Children With Life-Threatening Conditions and Their Parents
|
N/A | |
| Active, not recruiting |
NCT03445858 -
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
|
Early Phase 1 | |
| Terminated |
NCT05641324 -
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
|
Phase 1 | |
| Recruiting |
NCT04510636 -
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05504772 -
Precision Medicine for Every Child With Cancer
|
||
| Recruiting |
NCT05693831 -
myCare-102: Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports
|
||
| Recruiting |
NCT04421560 -
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
|
Phase 1/Phase 2 |